Diabetes patients in UK to get Eli Lilly drug, rivaling Ozempic

Both Novo Nordisk and Lilly have struggled to keep up with demand for the drugs, which are in shortage. 
Photo: George Frey/Reuters/Ritzau Scanpix
Photo: George Frey/Reuters/Ritzau Scanpix
By Naomi Kresge and Madison Muller, Bloomberg

(Bloomberg) - Eli Lilly’s Mounjaro, a diabetes drug that’s also nearing approval for weight loss, is set to reach UK patients after winning the backing of England’s influential health-cost regulator, National Institute for Health and Care Excellence (NICE). 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading